DDInter1346 DDInter1082
A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Orciprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Orciprenaline {u} (Compound) resembles {v} (Compound) Fenoterol
Orciprenaline {u} (Compound) resembles {v} (Compound) Terbutaline
Orciprenaline {u} (Compound) treats {v} (Disease) asthma
Orciprenaline {u} (Compound) binds {v} (Gene) ADRB2
Orciprenaline {u} (Compound) upregulates {v} (Gene) DDX10
Orciprenaline {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Orciprenaline {u} (Compound) downregulates {v} (Gene) SLC2A6
Orciprenaline {u} (Compound) causes {v} (Side Effect) Dizziness
Orciprenaline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Betamethasone
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Orciprenaline (Compound) resembles Fenoterol (Compound)
Orciprenaline (Compound) resembles Terbutaline (Compound)
Orciprenaline (Compound) treats asthma (Disease)
Orciprenaline (Compound) binds ADRB2 (Gene)
Orciprenaline (Compound) upregulates DDX10 (Gene)
Orciprenaline (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Orciprenaline (Compound) downregulates SLC2A6 (Gene)
Orciprenaline (Compound) causes Dizziness (Side Effect)
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Betamethasone